Evaluation of the Cardio protective Effect of Melatonin in Acute Aluminum Phosphide Poisoning: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR201911790018554

Enrollment

Registered

2019-11-11

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aluminum phosphide poisoning

Interventions

melatonin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All admitted cases above 18 years with acute aluminum phosphide poisoning will be included in this study.

Exclusion criteria

Exclusion criteria: • Cases ingested or exposed to other substances in addition to the phosphide. • Cases with delayed presentation. • Cases with pre-exciting disease (e.g. cardiovascular disease, renal

Design outcomes

Primary

Measure	Time frame
oDetermination of troponin I level and Arterial Blood Gases and oLipid peroxidation (LPO) assessment oTotal antioxidant capacity assessment	—

Secondary

Measure	Time frame
• Mortality. • Need for ventilation. • Duration of hospital stay	—

Countries

Egypt

Contacts

Public Contactrabab el kelany

faculty of medicine tanta university

rababkelany@yahoo.com+201001957313

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026